Format
Sort by

Send to

Choose Destination

Search results

Items: 2

1.

Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial.

Green RC, Schneider LS, Amato DA, Beelen AP, Wilcock G, Swabb EA, Zavitz KH; Tarenflurbil Phase 3 Study Group..

JAMA. 2009 Dec 16;302(23):2557-64. doi: 10.1001/jama.2009.1866.

2.

Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial.

Sevigny JJ, Ryan JM, van Dyck CH, Peng Y, Lines CR, Nessly ML; MK-677 Protocol 30 Study Group..

Neurology. 2008 Nov 18;71(21):1702-8. doi: 10.1212/01.wnl.0000335163.88054.e7.

PMID:
19015485

Supplemental Content

Loading ...
Support Center